Geistlich Pharma AG has ended the year 2012 on a very good note. Despite the difficult economic situation in its main market, Europe, Geistlich has continued to achieve good rates of growth. This is explained by the balanced geographical mix and long-term strategy of the company, which remains 100 per cent privately owned.
Growth from the BRIC nations
Over the past few years, Geistlich Pharma has invested heavily in its geographical expansion. The latest addition to its global presence occurred at the beginning of 2012, when Geistlich Pharma North America commenced operations as the company’s eighth subsidiary. Since spring 2012, Geistlich Pharma has been selling its bone substitute material <link internal-link internal link in current>Geistlich Bio-Oss<link internal-link internal link in current>® in Japan too. Previously, Geistlich Pharma established subsidiaries in South Korea (2011) and Brazil (2010). In 2008, new companies in France and China were added to its existing subsidiaries in the UK, Germany and Italy. This mix of east and west and of established and emerging markets is now paying off, with the BRIC nations in particular delivering attractive rates of growth.
Expertise in developing regeneration products
However, this expansion strategy is not the only factor behind the company‘s success in 2012. Geistlich Pharma is a privately owned Swiss family company which remains true to its roots while simultaneously moving with the times and concentrating on its strengths. Thus in 2012 the division active in dentistry launched <link internal-link internal link in current>Geistlich Bio-Oss Pen<link internal-link internal link in current>®. This is based on a new way of administering the bone substitute material, which has been established since 1986, enabling practitioners to optimise their application of the material. To date, Geistlich has launched Pen on the European market, where it has met with an extremely positive response. The new product was premiered at the Europerio Congress in Vienna at the beginning of June.
This strategy of a balanced geographical mix and new products based on Geistlich Pharma’s expertise in the field of regeneration will be continued by the company in 2013. Moreover, Geistlich plans to drive forward its three divisions Biomaterials, Surgery and Medical on the basis of “sustainable” research and science.